Role of nanotechnology for enzyme replacement therapy in lysosomal diseases. A focus on Gaucher's disease

Current Medicinal Chemistry

Volumn 23, Issue 9, 2016, Pages 929-952

  Martin Banderas, L ^a   Holgado, M A ^a   Duran Lobato, M ^a   Infante, J J ^b   Alvarez Fuentes, J ^c   Fernandez Arevalo, M ^a  

^a UNIVERSITY OF SEVILLE   (Spain)

^b Bionaturis   (Spain)

^c NONE

Author keywords

Enzyme therapy replacement; Gaucher's disease; Lysosomal diseases; Nanotechology; Targeting

Indexed keywords

CHAPERONE; GLUCOSYLCERAMIDASE; HYBRID PROTEIN; NANOCARRIER; ENZYME;

BLOOD BRAIN BARRIER; BONE MARROW TRANSPLANTATION; CYTOLOGY; DRUG TARGETING; ENZYME REPLACEMENT; FABRY DISEASE; GAUCHER DISEASE; GENE THERAPY; GLYCOGEN STORAGE DISEASE TYPE 2; HUMAN; HURLER SYNDROME; LYSOSOME STORAGE DISEASE; MAROTEAUX LAMY SYNDROME; MUCOPOLYSACCHARIDOSIS; NANOTECHNOLOGY; REVIEW; TRANSCYTOSIS; NANOMEDICINE; PROCEDURES;

ENZYME REPLACEMENT THERAPY; ENZYMES; GAUCHER DISEASE; HUMANS; NANOMEDICINE;

EID: 84964450460     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867323666160210130608     Document Type: Review

References (157)

1. Cooper, G.M. The Cell, A Molecular Approach, 2nd ed.; Boston University, 2000.
2. Futerman, A.H.; van Meer, G. The cell biology of lysosomal storage disorders. Nature, 2004, 5, 554-565.
3. Enzyme-Replacement Therapies for Lysosomal Storage Diseases. Technical Brief, number 12. Agency for Healthcare Research and Quality, 2013.
4. Vellodi, A. Lysosomal storage disorders. Brit. J. Haematol., 2004, 128, 413-431.
5. Arai, K.; Shimaya, A.; Hiratani, N.; Ohkuma, S. Purification and characterization of lysosomal H(+)-ATPase. An anion-sensitive v-type H(+)-ATPase from rat liver lysosomes. J. Biol. Chem., 1993, 268, 5649-5660.
6. Eskelinen, E.L.; Tanaka, Y., Saftig, P. At the acidic edge: emerging functions for lysosomal membrane proteins. Trends Cell Biol., 2003, 13, 137-145.
7. Lieberman, A.P., Puertollano, R., Raben, N., Slaugenhaupt, S., Walkley, S.U., Ballabio, A. Autophagy in lysosomal storage disorders. Autophagy, 2012, 8, 719-730.
8. Journet, A.; Chapel, A.; Kieffer, S.; Roux, F.; Garin, J. Proteomic analysis of human lysosomes: application to monocytic and breast cancer cells. Proteomics, 2002, 2, 1026-1040.
9. Goldstein, J.L.; Brown, M.S.; Anderson, R.G., Russell, D.W., Schneider, W.J. Receptor-mediated endocytosis: concepts emerging from the LDL receptor system. Annu. Rev. Cell Biol., 1985, 1, 1-39.
10. Lodish, H.; Berk, A.; Zipursky, S.L. In: Receptor-Mediated Endocytosis and the Sorting of Internalized Proteins in Molecular Cell Biology, Freeman, W.H., Ed.; 4th ed., New York, 2000, Section 17.9 (Available from: http://www.ncbi.nlm.nih.gov/books/NBK21639/).
11. Pavelka, M.; Roth, J. Receptor-Mediated Endocytosis Via Clathrin-Coated Vesicles and Virus Endocytosis in Functional Ultrastructure, 2nd ed.; Springer Wien: New York, 2010.
12. Settembre, C. Fraldi, A., Medina, D.L., Ballabio, A. Signals for the lysosome: a control center for cellular clearance and energy metabolism. Nat Rev Mol Cell Biol. 2013, 14, 283-296.
13. Dhami, R.; Schuchman, E.H. Mannose-6-phosphate receptor-mediated uptake is defective in acid sphingomyelinasedeficient macrophages: implications for Niemann-Pick disease enzyme replacement therapy. J. Biol. Chem., 2003, 279, 1526-1532.
14. Ohashi, T. Enzyme replacement therapy for lysosomal storage diseases. Pediatr. Endocrinol. Rev. 1, 2012, 26-34.
15. Wang, F.; Song, W.; Brancati, G.; Segatori, L. Inhibition of endoplasmic reticulum-associated degradation rescues native folding in loss of function protein misfolding diseases. J. Biol. Chem., 2011, 286, 43454-43564.
16. Reuser, A.J.; Drost, M.R. Lysosomal dysfunction, cellular pathology and clinical symptoms: basic principles. Acta Paediatr., 2006, Suppl. 95, 77-82.
17. Gieselmann, V. What can cell biology tell us about heterogeneity in lysosomal storage diseases? Acta Paediatr., 2005, Suppl. 94, 80-86.
18. Zhao, H.; Bailey, L.A.; Grabowski, G.A. Enzyme therapy of Gaucher disease: clinical and biochemical changes during production of and tolerization forneutralizing antibodies, Blood Cells Mol. Dis., 2003, 30, 90-96.
19. Dekiwadia, C.D.; Lawrie, A.C.; Fecondo, J.V. Peptidemediated cell penetration and targeted delivery of gold nanoparticles into lysosomes. J. Pept. Sci., 2012, 18, 527-534.
20. Papademetriou, J.; Garnacho, C.; Serrano, D.; Bhowmick, T.; Schuchman, E.H.; Muro, S. Comparative binding, endocytosis, and biodistribution of antibodies and antibodycoated carriers for targeted delivery of lysosomal enzymes to ICAM-1 versus transferrin receptor. J. Inherit. Metab. Dis., 2013, 36, 467-477.
21. Brady, R.O.; Schiffmann, R. Clinical Features of and Recent Advances in Therapy for Fabry Disease. The Journal of the American Medical Association, 2000, 284(21), 2771-2775 (doi:10.1001/jama.284.21.2771).
22. Clarke, L.A. The mucopolysaccharidoses: a success of molecular medicine. Expert Rev. Mol. Med., 2008, 10, e1 (doi:10.1017/S1462399408000550).
23. Scriver, C.R.; Beaudet, A.L.; Sly, W.S.; Valle, D. (eds.) The Metabolic and Molecular Basis of Inherited Disease, 7th edit.; McGraw-Hill; New York, 1995.
24. Suzuki K; Vanier M.T. Lysosomal Diseas. In: Basic Neurochemistry: Molecular, Cellular and Medical Aspects, 7th edition (ed.: Brady, S.; Siegel, G.; Albers, R.W.; Price, D.); Elsevier Academic Press; San Diego, California, 2005.
25. Rovensky, J.; Payer, J.; Herold, M. (edit.) Dictionary of Rheumatology; Springer; Berlin, 2015, p 207.
26. Muenzer, J.; Wraith, J.E.; Beck, M.; Giugliani, R.; Harmatz, P.; Eng, C.M.; Vellodi, A.; Martin, R.; Ramaswami, U.; Gucsavas-Calikoglu, M.; Vijayaraghavan, S.; Wendt, S.; Puga, A.; Ulbrich, B.; Shinawi, M.; Cleary, M.; Piper, D.; Conway, A.M.; Kimura, A. A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome). Genetics in Medicine, 2006, 8, 465-473 (doi:10.1097/01.gim.00002324-77.37660.fb).
27. Wraith, J.E.; Scarpa, M.; Beck, M.; Bodamer, O.A.; de Meirleir, L.; Guffon, N.; Lund, Malm, G.; Van der Ploeg, A.T.; Zeman, J. Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy. European Journal of Pediatrics, 2008, 167(3), pp 267-277 (doi:10.1007/s00431-007-0635-4).
28. Love, S.; Louis, D.; Ellison, D.W (editors). Greenfield's Neuropathology, vol 1, 8th edit.; CRC Press; Boca Raton, Florida, 2008.
29. Whelan, W.J.; Cameron, M.P. Glycogen Storage Disease, Type II. In: Ciba Foundation Symposium-Control of Glycogen Metabolism, John Wiley & Sons, Ltd.; Chichestre (UK), 1964 (published online: 30 may 2008, doi: 10.1002/9780470719343.ch25).
30. Amalfitano, A.; Bengur, A.R.; Morse, R.P.; Majure, J.M.; Case, L.E.; Veerling, D.L.; Mackey, J.; Kishnani, P.; Smith, W.; McVie-Wylie, A.; Sullivan, J.A.; Hoganson, G.E.; Phillips, J.A. 3rd.; Schaefer, G.B.; Charrow, J.; Ware, R.E.; Bossen, E.H.; Chen, Y.T. Recombinant human acid alphaglucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I/II clinical trial. Genet. Med., 2001, 3(2), 132-138.
31. Haberland, C. Clinical Neuropathology; Demos Medical Publishing, LLC.; New York, 2006; p 179.
32. Leslie, N.B.; Tinkle, T. Glycogen Storage Disease Type II (Pompe Disease) in Gene Reviews, Pagon, R.A. (ed.), Available from: http://www.ncbi.nlm.nih.gov/books/NBK1261/.
33. Stern, G. Niemann-Pick's and Gaucher's disease. Parkinsonism Relat. D., 2014, 20S1, S143-S146.
34. Lee, R.E. The pathology of Gaucher disease. Prog. Clin. Biol. Res., 1982, 95, 177-217.
35. Brady, R.O.; Barton, N.W.; Grabowski, G.A. The role of neurogenetics in Gaucher disease. Arch. Neurol., 1993, 50, 1212-1224.
36. Zhao, H.; Bailey, L.A.; Elsas, L.J.; Grinzaid, K.A.; Grabowski, G.A. Gaucher disease: In vivo evidence for allele dose leading to neuronopathic and non-neuronopathic phenotypes. Am. J. Med. Genet., 2003, 116, 52-56.
37. Ho, R.J.Y.; Gibaldi, M. Biotechnology and Biopharmaceuticals: Transforming Proteins and Genes into Drugs; John Wiley & Sons, Inc.; New York, 2004; p. 257.
38. Moran, N. Shire's replacement enzymes validate gene activation. Nature Biotechnology, 2010, 28, 1139-1140 (doi:10.1038/nbt1110-1139a).
39. Swiech, K.; Picanco-Castro, V.; Covas, D.T. Human cells: New platform for recombinant therapeutic protein production. Protein Expression and Purification, 2012, 84, 147-153.
40. Connock, M.; Burls, A.; Frew, E.; Fry-Smith, A.; Juarez-Garcia, A.; McCabe, C.; Wailoo, A.; Abrams, K.; Cooper, N.; Sutton, A.; O'Hagan, A.; Moore, D. The clinical effectiveness and cost-effectiveness of enzyme replacement therapy for Gaucher's disease: a systematic review. Health Technology Assessment, 2006; 10,(24) (disponible en http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0015148).
41. Zimran, A.; Elstein, D. Management of Gaucher disease: enzyme replacement therapy. Pediatr. Endocrinol. Rev. 2014, 12(1), 82-7.
42. Sawkar, A.R.; Cheng, W.; Beutler, E.; Wong, C.; Balch, W.E.; Kelly, J.W. Chemical chaperones increase the cellular activity of N370S β-glucosidase: A therapeutic strategy for Gaucher disease. Proc. Natl. Acad. Sci., 2002, 99(24), 15428-15433.
43. Weinreb, N. J.; Deegan, P.; Kacena, K.A.; Mistry, P.; Pastores, G.M.; Velentgas, P.; vom Dahl, S. Life expectancy in Gaucher disease type 1. Am. J. Hematol., 2008, 83, 896-900.
44. Cassinerio, E.; Graziadei, G.; Poggiali, E. Gaucher disease: A diagnostic challenge for internists. Eur. J. Intern. Med., 2014, 25, 117-124.
45. Brady, R.O.; Pentchev, P.G.; Gal, A.E.; Hibbert, S.R.; Dekaban, A.S. Replacement therapy for inherited enzyme deficiency. Use of purified glucocerebrosidase in Gaucher's disease. N. Engl. J. Med., 1974, 291, 989-993.
46. Barton, N.W.; Brady, R.O.; Dambrosia, J.M.; Di Bisceglie, A.M.; Doppelt, S.H.; Hill, S.C.; Mankin, H.J.; Murray, G.J.; Parker, R.I.; Argoff, C.E. Replacement therapy for inherited enzyme deficiency macrophage-targeted glucocerebrosidase for Gaucher's disease. N. Engl. J. Med., 1991, 324, 1464-1470.
47. Grabowski, G.A.; Barton, N.W.; Pastores, G.; Dambrosia, J.M.; Banerjee, T.K.; McKee, M.A.; Parker, C.; Schiffmann, R.; Hill, S.C.; Brady, R.O. Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannoseterminated glucocerebrosidase from natural and recombinant sources. Ann. Intern. Med., 1995, 122, 33-39.
48. Mistry, P.K.; Wraight, E.P.; Cox, T.M. Therapeutic delivery of proteins to macrophages: implications for treatment of Gaucher's disease. Lancet, 1996, 348, 1555-1559.
49. Goldman, D.P.; Clarke, A.E.; Garber, A.M. Creating the costliest orphan. The Orphan Drug Act in the development of Ceredase. Int. J. Technol. Assess. Health Care, 1992, 8, 583-597.
50. Van Dussen, L.; Biegstraaten, M.; Hollak, C.E.; Dijkgraaf, M.G. Cost-effectiveness of enzyme replacement therapy for type 1 Gaucher disease. Orphanet J. Rare Dis., 2014, 9(51), doi:10.1186/1750-1172-9-51.
51. Elstein, D.; Cohn, G.M.; Wang, N.; Djordjevic, M.; Brutaru, C.; Zimran, A. Early achievement and maintenance of the therapeutic goals using velaglucerase alfa in type 1 Gaucher disease. Blood Cells Mol. Dis., 2011, 46, 119-123.
52. Shaaltiel, Y.; Bartfeld, D.; Hashmueli, S.; Baum, G.; Brill-Almon, E.; Galili, G.; Dym, O.; Boldin-Adamsky, S.A.; Silman, I.; Sussman, J.L.; Futerman, A.H.; Aviezer, D. Production of glucocerebrosidase with terminal mannose glycans for enzyme replacement therapy of Gaucher's disease using a plant cell system. Plant Biotechnol. J., 2007, 5, 579-590.
53. Brumshtein, B.; Salinas, P.; Peterson, B.; Chan, V.; Silman, I.; Sussman, J.L.; Savickas, P.J.; Robinson, G.S.; Futerman, A.H. Characterization of gene-activated human acid-beta glucosidase: crystal structure, glycan composition, and internalization into macrophages. Glycobiology, 2010, 20, 24-32.
54. Reczek, D.; Schwake, M.; Schroder, J.; Hughes, H.; Blanz, J.; Jin, X.; Brondyk, W.; Van Patten, S.; Edmunds, T.; Saftig, P. LIMP-2 is a receptor for lysosomal mannose-6-phosphate-independent targeting of betaglucocerebrosidase. Cell, 2007,131, 770-783.
55. Prabakaran, T.; Nielsen, R.; Larsen, J.V.; Sorensen, S.S.; Feldt-Rasmussen, U.; Saleem, M.A.; Petersen, C.M.; Verroust, P.J.; Christensen, E.I. Receptor-mediated endocytosis of α-galactosidase A in human podocytes in Fabry disease. PLoS One, 2011, 6, e25065.
56. Deegan, P.B.; Cox, T.M. Imiglucerase in the treatment of Gaucher disease: a history and perspective, Drug Des. Devel. Ther., 2012, 6, 81-106.
57. Hoffmann, B.; Mayatepek, E. Neurological manifestations in lysosomal storage disorders-from pathology to first therapeutic possibilities. Neuropediatrics, 2005, 36, 285-289.
58. Schueler, U.; Kaneski, C.; Murray, G.; Sandhoff, K.; Brady, R.O. Uptake of mannose-terminal glucocerebrosidase in cultured human cholinergic and dopaminergic neuron cell lines. Neurochem. Res., 2002, 27, 325-330.
59. Cox, T.; Lachmann, R.; Hollak, C.; Aerts, J.; van Weely, S.; Hrebicek, M.; Platt, F.; Butters, T.; Dwek, R.; Moyses, C.; Gow, I.; Elstein, D.; Zimran, A. Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis. Lancet, 2000, 355, 1481-1485.
60. Cox, T.M.; Aerts, J.M.; Andria, G.; Beck, M.; Belmatoug, N.; Bembi, B.; Chertkoff, R.; Vom Dahl, S.; Elstein, D.; Erikson, A.; Giralt, M.; Heitner, R.; Hollak, C.; Hrebicek, M.; Lewis, S.; Mehta, A.; Pastores, G.M.; Rolfs, A.; Miranda, M.C.; Zimran, A. The role of the iminosugar Nbutyldeoxynojirimycin (miglustat) in the management of type I (non-neuronopathic) Gaucher disease: a position statement. J. Inherit. Metab. Dis., 2003, 26, 513-526.
61. Cox, T.M. Eliglustat tartrate, an orally active glucocerebroside synthase inhibitor for the potential treatment of Gaucher disease and other lysosomal storage diseases. Curr. Opin. Investig. Drugs, 2010, 11, 1169-1181.
62. Jakobkiewicz-Banecka, J.; Wegrzyn, A.; Wegrzyn, G. Substrate deprivation therapy: a new hope for patients suffering from neuronopathic forms of inherited lysosomal storage diseases. J. Appl. Genet., 2007, 48, 383-388.
63. Lyseng-Williamson, K.A. Miglustat: a review of its use in Niemann-Pick disease type C. Drugs, 2014, 74, 61-74.
64. Grubb, J.H.; Vogler, C.; Sly, W.S. New strategies for enzyme replacement therapy for lysosomal storage diseases. Rejuvenation Res., 2010, 13, 229-236.
65. Schuchman, E.H. and Muro, S. The development of enzyme replacement therapy for Lysosomal diseases: Gaucher disease and beyond (editors). In: Gaucher disease Futerman, A.H,; Zimran, A.; CRC Press, Boca Raton, Florida; 2006; pp. 129-132.
66. Schmidt, S.R. Fusion proteins as biopharmaceuticals-Applications and challenges. Curr. Opin. Drug Discov. Devel., 2009, 12, 284-295.
67. Krivit, W.; Peters, C.; Shapiro, E.G. Bone marrow transplantation as effective treatment of central nervous system disease in globoid cell leukodystrophy, metachromatic leukodystrophy, adrenoleukodystrophy, mannosidosis, fucosidosis, aspartylglucosaminuria, Hurler, Maroteaux-Lamy, and Sly syndromes, and Gaucher disease type III. Curr. Opin. Neurol., 1999, 12(2), 167-176.
68. Fabrega, S.; Lehn, P. Gene therapy of Gaucher's and Fabry's diseases: current status and prospects. J. Soc. Biol., 2002, 196, 175-181.
69. http://www.gauchercare.com/en/patient/treatment/FutureRe search.aspx (Accessed March, 2015).
70. Jeyakumar, M.; Dwek, R.A.; Butters, T.D.; Platt, F.M. Storage solutions: treating lysosomal disorders of the brain. Nat. Rev., 2005, 6, 1-12.
71. Olivier, J.C.; Fenart, L.; Chauvet, R.; Pariat, C.; Cecchelli, R.; Couet, W. Indirect evidence that drug brain targeting using polysorbate 80 coated polybutylcyanoacrylate nanoparticles is related to toxicity. Pharm. Res., 1999, 16, 1836-1842.
72. Ramge, P.; Unger, R.E.; Oltrogge, J.B.; Zenker, D.; Begley, D.; Kreuter, J.; Von Briesen, H. Polysorbate-80 coating enhances uptake of polybutylcyanoacrylate (PBCA)-nanoparticles by human and bovine primary brain capillary endothelial cells. Eur. J. Neurosci., 2000, 12, 1931-1940.
73. Zhao, L.X.; Liu, A.C.; Yu, S.W. The permeability of puerarin loaded poly(butylcyanoacrylate) nanoparticles coated with polysorbate 80 on the blood-brain-barrier and its protective effect against cerebral ischemia/reperfusion injury. Biol. Pharm. Bull., 2013, 36, 1263-1270.
74. Ambruosi, A.; Gelperina, S.; Khalansky, A.; Tanski, S.; Theisen, A.; Kreuter, J. Influence of surfactants, polymer and doxorubicin loading on the anti-tumour effect of poly(butyl cyanoacrylate) nanoparticles in a rat glioma model. J. Microencap., 2006, 23, 582-592.
75. Gelperina, S.; Maksimenko, O.; Khalansky, A.; Vanchugova, L.; Shipulo, E.; Abbasova, K.; Berdiev, R.; Wohlfart, S.; Chepurnova, N.; Kreuter, J. Drug delivery to the brain using surfactant-coated poly(lactide-co-glycolide) nanoparticles: Influence of the formulation parameters. Eur. J. Pharm. Biopharm., 2010, 74, 157-163.
76. S.Wohlfart, A.S. Khalansky, S. Gelperina,O.Maksimenko, C. Bernreuther, M. Glatzel, J. Kreuter, Efficient chemotherapy of rat glioblastoma using doxorubicin-loaded PLGA nanoparticles with different stabilizers. PLoS One, 2011, 6, e19121.
77. Wohlfart, S.; Gelperina, S.; Kreuter, J. Transport of drugs across the blood-brain barrier by Nanoparticles. J. Control. Release, 2012, 161, 264-273.
78. Kreuter, J. Mechanism of polymeric nanoparticle-based drug transport across the blood-brain barrier (BBB). J. Microencapsul., 2013, 30, 49-54.
79. Kreuter, J. Drug delivery to the central nervous system by polymeric nanoparticles: What do we know? Adv Drug Deliv. Rev., 2014, 71, 2-14.
80. Beduneau, A.; Saulnier, P.; Benoit, J.P. Active targeting of brain tumors using nanocarriers. Biomaterials, 2007, 28, 4947-4967.
81. Bennewitz, M.F.; Saltzman, W.M. Nanotechnology for delivery of drugs to the brain for epilepsy. Neurotherapeutics, 2009, 6, 323-336.
82. Alam, M.; Bega, S.; Samadb, A.; Babootaa, S.; Kohlia, K.; Ali, J.; Ahujac, A.; Akbard, M. Strategy for effective brain drug delivery. Eur. J. Pharm. Sci., 2010, 40, 385-403.
83. Pardridge, W.M. Transport of small molecules through the blood-brain barrier: biology and methodology. Adv Drug Deliv. Rev., 1995, 15, 5-36.
84. Mora, M.; Sagrista, M.L.; Trombetta, D.; Bonina, F.P.; De Pasquale, A.; Saija, A. Design and characterization of liposomes containing longchain N-acylPEs for brain delivery: penetration of liposomes incorporating GM1 into the rat brain. Pharm. Res., 2002, 19, 1430-1438.
85. Lockman, P.R.; Mumper, R.J.; Khan, M.A.; Allen, D.D. Nanoparticle technology for drug delivery across bloodbrain barrier. Drug Dev. Ind. Pharm., 2002, 28, 749-771.
86. Fenart, L.; Casanova, A.; Dehouck, B.; Duhem, C.; Slupek, S.; Cecchelli, R.; Betbeder, D. Evaluation of effect of charge and lipid coating on ability of 60-nm nanoparticles to cross an in vitro model of the blood-brain barrier. J. Pharmacol. Exp. Ther., 1999, 291, 1017-1022.
87. Chang, J.; Jallouli, Y.; Kroubi, M.; Yuan, X.; Feng, W.; Kang, C.; Pu, P.; Betbeder, D. Characterization of endocytosis of transferrincoated PLGA nanoparticles by the blood-brain barrier. Int. J. Pharm., 2009, 379, 285-292.
88. Ulbrich, K.; Hekmatara, T.; Herbert, E.; Kreuter, J. Transferrin-and transferrin-receptor-antibody-modified nanoparticles enable drug delivery across the blood-brain barrier (BBB). Eur. J. Pharm. Biopharm., 2009, 71, 251-256.
89. Loscher, W.; Potschka, H. Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases. Prog. Neurobiol., 2005, 76, 22-76.
90. Mistry, A.; Glud, S.Z.; Kjems, J.; Randel, J.; Howard, K.A.; Stolnik, S.; Illum, L. The effect of physicochemical properties on intranasal nanoparticle transit into murine olfactory epithelium. J. Drug Target., 2009, 17, 543-552.
91. Drin, G.; Rousselle, C.; Scherrmann, J.M.; Rees, A.R.; Temsamani, J. Peptide delivery to the brain via adsorptivemediated endocytosis: advances with SynB vectors. AAPS Pharm. Sci., 2002, 4, article 26.
92. Temsamani, J.; Laruelle, C. Synb peptide vectors. A new approach to drug delivery. Chem. Today, 2010, 28, 18-20.
93. Herve, F.; Ghinea, N.; Scherrmann, J.M. CNS Delivery Via Adsorptive Transcytosis. The AAPS Journal, 2008, 10, 455-472.
94. Bickel, U.; Yoshikawa, T.; Pardridge, W.M. Delivery of peptides and proteins through the blood-brain barrier. Adv. Drug Deliv. Rev., 2001, 46, 247-279.
95. Fleige, E.; Quadir, M.A.; Haag, R. Stimuli-responsive polymeric nanocarriers for the controlled transport of active compounds: Concepts and applications. Adv. Drug Deliver. Rev., 2012, 64, 866-884.
96. Onaca-Fischer, O.; Liu, J.; Inglin, M.; Palivan, C.G. Polymeric nanocarriers and nanoreactors: a survey of possible therapeutic applications. Curr. Pharm. Design, 2012, 18, 2622-2643.
97. Pirooznia, N.; Hasannia, S.; Lotfi, A.S.; Ghanei, M. Encapsulation of Alpha-1 antitrypsin in PLGA nanoparticles: In Vitro characterization as an effective aerosol formulation in pulmonary diseases. J. Nanobiotechnology, 2012, 10, 20.
98. Dziubla, T.D.; Karim, A.; Muzykantov, V.R. Polymer nanocarriers protecting active enzyme cargo against proteolysis. J. Control. Release, 2005, 102, 427-439.
99. Ambati, J., Lopez, A.M., Cochran, D., Wattamwar, P., Bean, K.; Dziubla, T.D.; Rankin, S.E. Engineered silica nanocarriers as a high-payload delivery vehicle for antioxidant enzymes. Acta Biomaterialia, 2012, 8, 2096-2103.
100. Klyachko, N.; Manickam, D.; Brynskikh, A.M.; Uglanova, S.V.; Li, S.; Higginbotham, S.M.; Bronich, T.K.; Batrakova, E.V.; Kabanov, A.V. Cross-linked antioxidant nanozymes for improved delivery to CNS. Nanomed-Nanotechnol., 2012, 8, 119-129.
101. Meng, X.; Xu, G.; Zhou, Q.L.; Wu, J.P.; Yang, L.R. Improvements of lipase performance in high-viscosity system by immobilization onto a novel kind of poly(methylmethacrylate-co-divinylbenzene) encapsulated porous magnetic microsphere carrier. J. Mol. Catal. B: Enzym., 2013, 89, 86-92.
102. Moghadam, T.T.; Ranjbar, B.; Khajeh, K. Conformation and activity of lysozyme on binding to two types of gold nanorods: A comparative study. Int. J. Biol. Macromol., 2012, 51, 91-96.
103. Hsu, J. Northrup, L.; Bhowmick, T.; Muro, S. Enhanced delivery of alpha-glucosidase for Pompe disease by ICAM-1-targeted nanocarriers: comparative performance of a strategy for three distinct lysosomal storage disorders. Nanomed-Nanotechnol., 2012, 8, 731-739.
104. Hsu, J.; Bhowmick, T.; Burks, S.R.; Kao, J.P.Y.; Muro, S. Enhancing Biodistribution of Therapeutic Enzymes In Vivo by Modulating Surface Coating and Concentration of ICAM-1-Targeted Nanocarriers. J. Biomed. Nanotechnol., 2014, 10, 345-354.
105. Papademetriou, J.; Garnacho, C.; Schuchman, E.H.; Muro, S. In vivo performance of polymer nanocarriers duallytargeted to epitopes of the same or different receptors. Biomaterials, 2013, 34, 3459-3466.
106. Garnacho, C.; Dhami, R.; Dziubla, T.; Leferovich, J.; Schuchman, E.H.; Muzykantov, V.; Muro, S. Delivery of acidsphingolyelinase in normal and Niemman-Pick disease mice using intercellular adhesion molecule-1-targeted polymer nanocarriers. J. Pharmacol. Exp. Ther., 2008, 325, 400-408.
107. Muro, S.; Cui, X.; Gajewski, C.; Murciano, J.C.; Muzykantov, V.R.; Koval, M. Slow intracellular trafficking of catalase nanoparticles targeted to ICAM-1 protects endothelia cells from oxidative stress. Am. J. Physiol. Cell Physiol., 2003, 285, 1339-1347.
108. Aerts, J.M.; van Breemena, M.J.; Bussinka, A.P.; Brinkmanb, J.; Hollakc, C.E.M.; Langeveldc, M.; Linthorstc, G.E.; Vedderc, A.C.; de Fost, M. The blood-brain barrier and treatment of lysosomal storage diseases. Int. Congr. Ser., 2005, 1277, 19-31.
109. Martin-Banderas, L., Holgado, M.A., Venero, J.L., Alvarez-Fuentes, J., Fernandez-Arevalo, M. Nanostructures for drug delivery to the brain. Curr. Med. Chem., 2011, 18, 5303-5321.
110. Wohlfart, S.; Gelperina, S.; Kreuter, J. Transport of drugs across the blood-brain barrier by Nanoparticles. J. Control. Release, 2012, 161, 264-273.
111. Blasi, P.; Giovagnoli, S.; Schoubben, A.; Ricci, M.; Rossi, C. Solid lipid nanoparticles for targeted brain drug delivery. Adv. Drug Deliv. Rev., 2007, 59, 454-477.
112. Kreuter, J. Mechanism of polymeric nanoparticle-based drug transport across the blood-brain barrier (BBB). J. Microencapsul., 2013, 30, 49-54.
113. Vlieghe, P.; Khrestchatisky, M. Medicinal Chemistry Based Approaches and Nanotechnology-Based Systems to Improve CNS Drug Targeting and Delivery Medicinal. Res. Rev., 2013, 33, 457-516.
114. Tancini, B. Tosi, G. Bortot, B. Use of Polylactide-Co-Glycolide-Nanoparticles for Lysosomal Delivery of a Therapeutic Enzyme in Glycogenosis Type II Fibroblasts. J. Nanosci.Nanotech. 2015, 15, 2657-2666.
115. Wang, J.J.; Zeng, Z.W.; Xiao, R.Z.; Xie, T.; Zhou, G.L.; Zhan, X.R.; Wang, S.L. Recent advances of chitosan Nanoparticles as drug Carriers. Int. J. Nanomedicine, 2011, 6, 765-774.
116. Olivier, J.C. Drug transport to brain with targeted nanoparticles. NeuroRx, 2005, 2, 108-119
117. Muehlstein, A.; Gelperina, S.; Kreuter, J. Development of nanoparticlebound arylsulfatase B for enzyme replacement therapy of mucopolysaccharidosis VI. Pharmazie, 2013, 68, 549-55.
118. Muehlstein, A.; Gelperina, S.; Shipulo, E; Maksimenko, O, Kreuter J. Arylsulfatase A bound to poly(butyl cyanoacrylate) nanoparticles for enzyme replacement therapy-physicochemical evaluation. Pharmazie, 2014, 69, 518-524.
119. http://informahealthcare.com/doi/abs/10.1517/17425247. 2013.784742 (Accessed April, 2015).
120. Schnyder, A.; Huwyler, J. Drug Transport to Brain with Targeted Liposomes. NeuroRx, 2005, 2, 99-107.
121. Beduneau, A.; Saulniera, P.; Benoit, J.P. Active targeting of brain tumors using nanocarriers. Biomaterials, 2007, 28, 4947-4967.
122. Markoutsa, E.; Pampalakis, G.; Niarakis, A.; Romero, I.A.; Weksler, B.; Couraud, P.; Antimisiaris, S.G. Uptake and permeability studies of BBB-targeting immunoliposomes using the hCMEC/D3 cell line. Eur. J. Pharm. Biopharm., 2011, 77, 265-274.
123. Huwyler, J.; Wu, D.; Pardridge, W.M. Brain drug delivery of small molecules using immunoliposomes. Proc. Natl. Acad. Sci. USA, 1996, 93, 14164-14169.
124. Thekkedath, Ritesh; Koshkaryev, Alexander; Torchilin, Vladimir P. Lysosome-targeted octadecyl-rhodamine Bliposomes enhance lysosomal accumulation of glucocerebrosidase in Gaucher's cells in vitro. Nanomed., 2013, 8, 1055-1065.
125. Zensi, A.; Begley, D.; Pontikis, C.; Legros, C.; Mihoreanu, L.; Buchel, C.; Kreuter, J. Human serum albumin nanoparticles modified with apolipoprotein A-I cross the bloodbrain barrier and enter the rodent brain. J. Drug Target, 2010, 18, 842-848.
126. Korkusuz, H.; Ulbrich, K.; Welzel, K.; Koeberle, V.; Watcharin, W.; Bahr, U.; Chernikov, V.; Knobloch, T.; Petersen, S.; Huebner, F.; Ackermann, H.; Gelperina, S.; Kromen, W.; Hammerstingl, R.; Haupenthal, J.; Gruenwald, F.; Fiehler, J.; Zeuzem, S.; Kreuter, J.; Vogl, T.J.; Piiper, A. Transferrin-Coated Gadolinium Nanoparticles as MRI Contrast Agent. Mol. Imaging Biol., 2013, 15, 148-154.
127. Chopra, A. Transferrin-coated gadolinium-labeled human serum albumin nanoparticles. Molecular Imaging and Contrast Agent Database (MICAD). Bethesda (MD), National Center for Biotechnology Information (US), 2013.
128. Chen, Y.S.; Hung, Y.C.; Liau, I.; Lin, L.W.; Hong, M.Y.; Huang, G.S. In: Gold nanoparticles caused learning impairment in mice. Proceedings of Nanotechnology 2009: Life Sciences, Medicine, Diagnostics, Biomaterials and Composites, Anaheim, California (USA), June 21-25, 2009; vol. 2, pp. 379-382.
129. Chen, Y.S.; Hung, Y.C.; Lin, L.W.; Liau, I.; Hong, M.Y.; Huang, G.S. Size-dependent impairment of cognition in mice caused by the injection of gold nanoparticles. Nanotechnology, 2010, 21, no. 48, Article ID 485102.
130. Barua, S.; Mitragotri, S. Synergistic targeting of cell membrane, cytoplasm and nucleus of cancer cells using rodshaped nanoparticles. ACSnano, 2013, 7, 9558-9570.
131. Zhang, S.; Li, J.; Lykotrafitis, G.; Bao, G.; Suresh, S. Size-Dependent Endocytosis of Nanoparticles. Adv. Mater., 2009, 21, 419-424.
132. Holgado, M.A.; Martin-Banderas, L.; Alvarez-Fuentes, J.; Fernandez-Arevalo, M.; Arias, J.L. Drug targeting to cancer by nanoparticles surface functionalized with special biomolecules. Curr. Med. Chem., 2012, 19, 3188-3195.
133. Solomon, M.; D'Souza, G.M. Approaches to Achieving Sub-cellular Targeting of Bioactives Using Pharmaceutical Nanocarriers. In: Intracellular Delivery: Fundamentals and Applications; Aleš Prokop, Ed.; Springer, Berlin, 2011; pp. 57-72.
134. Castino, R.; De'moz, M.; Isidoro, C. Destination 'Lysosome': a target organelle for tumour cell killing? J. Mol. Recognit., 2003, 16, 337-348.
135. Bareford, L.M.; Swaan, P.W. Endocytic mechanisms for targeted drug delivery. Adv. Drug Deliv. Rev., 2007, 59, 748-758.
136. Qian, Z.M.; Li, H.; Sun, H.; Ho, K. Targeted drug delivery via the transferrin receptor-mediated endocytosis pathway. Pharmacol. Rev., 2002, 54, 561-587.
137. Ghosh, R.N.; Gelman, D.L.; Maxfield, F.R. Quantification of low density lipoprotein and transferrin endocytic sorting in HEp2 cells using confocal microscopy. J. Cell Sci., 1994, 107, 2177-2189.
138. Dunn, K.W.; Maxfield, F.R. Delivery of Ligands from Sorting Endosomes to Late Endosomes Occurs by Maturation of Sorting Endosomes. J. Cell Biol., 1992, 117, 301-310.
139. Muro, S.; Schuchman, E.H.; Muzykantov, V.R. Lysosomal enzyme delivery by ICAM-1-targeted nanocarriers bypassing glycosylation-and clathrin-dependent endocytosis. Mol. Ther., 2006, 13, 135-141.
140. Kolhar, P.; Anselmob, A.C.; Guptab, V.; Pantc, K.; Prabhakarpandianc, B.; Ruoslahtid, E.; Mitragotria, S. Using shape effects to target antibody-coated nanoparticles to lung and brain endothelium. PAN, 2013, 110, 10753-10758.
141. Hsu, J.; Hoenicka, J.; Muro, S. Targeting, endocytosis, and lysosomal delivery of active enzymes to model human neurons by ICAM-1-targeted nanocarriers. Pharma. Res, 2015, 32(4), 1264-1278.
142. Vacha, R.; Martinez-Veracoechea, F.J.; Frenkel, D. Receptor-mediated endocytosis of nanoparticles of various shapes. Nano Letters, 2011, 11, 5391-5395.
143. Gratton, S.E.A.; Ropp, P.A.; Pohlhaus, P.D.; Luft, J.C.; Madden, V.J.; Napier, M.E.; DeSimone, J.M. The effect of particle design on cellular internalization pathways. Porc. Natl. Acad. Sci. USA, 2008, 105, 11613-11818.
144. Yoo, J.W.; Doshi, N.; Mitragotri, S. Endocytosis and intracellular distribution of plga particles in endothelial cells: effect of particle geometry. Macromol. Rapid Commun., 2010, 31, 142-148.
145. El-Sayed, M., Hoffman, A.S.; Stayton, P.S. Smart polymeric carriers for enhanced intracellular delivery of therapeutic macromolecules. Expert Opin. Biol. Ther., 2005, 5, 1-10.
146. Woodrow, K.A.; Bennett, K.M.; Lo, D.D. Mucosal vaccine design and delivery. Annu. Rev. Biomed. Eng., 2012, 14, 17-46.
147. Zhou, K.; Wang, Y.; Huang, X.; Luby-Phelps, K.; Sumer, B.D.; Gao, J. Tunable, ultrasensitive ph-responsive nanoparticles targeting specific endocytic organelles in living cells. Angew. Chem. Int. Ed., 2011, 50, 6109-6114.
148. Ding, H.M.; Ma, Y.Q. Controlling cellular uptake of nanoparticles with pH-Sensitive Polymers, Sci. Rep., 2013, 3, 1-6.
149. Pentchev, P.G.; Brady, R.O. Isolation of glucocerebrosidase from human placental tissue. U.S. Patent 3,910,822, October 7, 1975.
150. Shorr, R.G.L.; Cho, M.O.; Gilbert, C.W.; Ginns, E.J.; Martin, B.M. Glycolipid enzyme-polymer conjugates. U.S. Patent 5,620,884, April 15, 1997.
151. Katre, N.V. The conjugation of proteins with polyethylene glycol and other polymers: Altering properties of proteins to enhance their therapeutic potential. Adv. Drug Deliv. Rev., 1993, 10, 91-114.
152. Fuertges, F.; Abuchowski, A. The clinical efficacy of poly(ethyleneglycol)-modified proteins. J. Control. Release, 1990, 11, 139-148.
153. Nucci, M.L.; Shorr, R.; Abuchowski, A. The therapeutic value of poly(ethylene glycol)-modified proteins. Adv. Drug Deliv. Rev., 1991, 6, 133-1519.
154. Garman, A.J. Conjugates of pharmaceutically useful proteins. U.S. Patent 4,935,465, June 19, 1990.
155. Shorr, R.G.L.; Cho, M.O.; Gilbert, C.W. Glycolipid enzyme-polymer conjugates. U.S. patent 5,705,153, December 8, 1998.
156. Whittington, R.; Goa, K.L. Alglucerase. A review of its therapeutic use in Gaucher's disease, Drugs, 1992, 44, 72-93.
157. Ginns, E.I.; Ostroff, G.R. Therapy for lysosomal enzyme deficiencies, U.S. Patent US 8,007,814, September 19, 2005.